Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ABUS Stock Forecast 2025-2026
$3.23
Current Price
$618.48M
Market Cap
Buy 3
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ABUS Price Targets
+122.4%
To High Target of $7.18
+59.3%
To Median Target of $5.14
+27.5%
To Low Target of $4.12
ABUS Price Momentum
-8.0%
1 Week Change
+2.9%
1 Month Change
+12.2%
1 Year Change
-1.2%
Year-to-Date Change
-31.6%
From 52W High of $4.72
+19.2%
From 52W Low of $2.71
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Arbutus Biopharma (ABUS) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ABUS and similar high-potential opportunities.
Latest ABUS Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, ABUS has a bullish consensus with a median price target of $5.14 (ranging from $4.12 to $7.18). Currently trading at $3.23, the median forecast implies a 59.3% upside. This outlook is supported by 3 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ABUS Analyst Ratings
3
Buy
1
Hold
0
Sell
ABUS Price Target Range
Low
$4.12
Average
$5.14
High
$7.18
Current: $3.23
Latest ABUS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ABUS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 28, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $5.00 |
| Jan 21, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $5.00 |
| Nov 20, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $5.00 |
| Nov 18, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $5.00 |
| Nov 7, 2024 | Chardan Capital | Buy | Maintains | $0.00 | |
| Nov 7, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $5.00 |
| Nov 6, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $4.50 |
| Sep 5, 2024 | Jefferies | Dennis Ding | Buy | Maintains | $7.00 |
| Aug 2, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $5.00 |
| Jun 7, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $5.00 |
| Jun 6, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $5.00 |
| Jun 5, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $4.00 |
| May 3, 2024 | Chardan Capital | Keay Nakae | Buy | Reiterates | $4.00 |
| Apr 4, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $4.00 |
| Mar 1, 2024 | Chardan Capital | Keay Nakae | Buy | Reiterates | $4.00 |
| Mar 1, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $5.00 |
| Sep 12, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
| Aug 4, 2023 | Chardan Capital | Keay Nakae | Buy | Reiterates | $6.00 |
| Aug 4, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
| Jul 11, 2023 | HC Wainwright & Co. | Buy | Reiterates | $0.00 |
Arbutus Biopharma Corporation (ABUS) Competitors
The following stocks are similar to Arbutus Biopharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Arbutus Biopharma Corporation (ABUS) Financial Data
Arbutus Biopharma Corporation has a market capitalization of $618.48M with a P/E ratio of -8.7x. The company generates $6.17M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -26.6% quarter-over-quarter, while maintaining an operating margin of -995.4% and return on equity of -68.8%.
Valuation Metrics
Market Cap
$618.48M
Enterprise Value
$515.38M
P/E Ratio
-8.7x
PEG Ratio
-9.5x
Price/Sales
100.2x
Growth & Margins
Revenue Growth (YoY)
-26.6%
Gross Margin
N/A
Operating Margin
-995.4%
Net Margin
0.0%
EPS Growth
-26.6%
Financial Health
Cash/Price Ratio
+19.8%
Current Ratio
8.2x
Debt/Equity
6.3x
ROE
-68.8%
ROA
-33.4%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Arbutus Biopharma Corporation (ABUS) Business Model
About Arbutus Biopharma Corporation
What They Do
Develops cures for chronic hepatitis B virus.
Business Model
Arbutus Biopharma operates in the biopharmaceutical sector, focusing on discovering and commercializing innovative therapies for chronic hepatitis B virus (HBV) infection. The company generates revenue through the development and potential commercialization of antiviral therapies, particularly leveraging its proprietary RNA interference technology to enhance immune response and target the virus.
Additional Information
The company is positioned as a leader in biotechnology, addressing significant unmet medical needs and contributing to public health advancements. Its commitment to pioneering solutions for viral infections reflects a broader goal of improving global health outcomes.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
44
CEO
Ms. Lindsay Androski J.D., M.B.A.
Country
United States
IPO Year
2007
Website
www.arbutusbio.comArbutus Biopharma Corporation (ABUS) Latest News & Analysis
Latest News
Quick Summary
Arbutus Biopharma presented promising data at EASL 2025, showing imdusiran can achieve a functional cure for chronic hepatitis B alongside VTP-300 and low-dose nivolumab. AB-101 is safe and well-tolerated.
Why It Matters
Positive clinical trial results for imdusiran and AB-101 may enhance Arbutus Biopharma's market position, potentially increasing investor confidence and stock value in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Arbutus (ABUS) is not expected to meet the criteria for a potential earnings beat in its upcoming report, indicating weaker performance expectations.
Why It Matters
Arbutus may underperform in its earnings report, indicating potential stock price weakness and influencing investor sentiment and decisions regarding the company.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Arbutus Biopharma (Nasdaq: ABUS) announced five abstracts accepted for presentation, including one late-breaker, at the EASL Congress 2025 in Amsterdam, from May 7-10, 2025.
Why It Matters
Positive news for Arbutus Biopharma as multiple abstracts accepted for a major conference can indicate strong research progress, potentially boosting investor confidence and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Arbutus Biopharma (ABUS) and Aveanna Healthcare (AVAH) performance details relative to their sector have been reported for this year. Further specifics were not provided.
Why It Matters
Performance comparisons reveal growth potential or risks relative to sector trends, influencing investment decisions for Arbutus Biopharma and Aveanna Healthcare.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Arbutus (ABUS) has been upgraded to a Zacks Rank #2 (Buy), indicating increasing optimism about its earnings prospects.
Why It Matters
Arbutus's Zacks Rank #2 upgrade signals positive earnings outlook, potentially boosting investor confidence and driving stock price appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Arbutus Biopharma is reducing its workforce by over 50% to enhance financial and operational efficiency.
Why It Matters
Arbutus Biopharma's workforce reduction signals cost-cutting measures, potentially improving profitability and operational focus, which could influence stock performance and investor sentiment.
Source: Market Watch
Market Sentiment:
Negative
Frequently Asked Questions About ABUS Stock
What is Arbutus Biopharma Corporation's (ABUS) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, Arbutus Biopharma Corporation (ABUS) has a median price target of $5.14. The highest price target is $7.18 and the lowest is $4.12.
Is ABUS stock a good investment in 2025?
According to current analyst ratings, ABUS has 3 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.23. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ABUS stock?
Wall Street analysts predict ABUS stock could reach $5.14 in the next 12 months. This represents a 59.3% increase from the current price of $3.23. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Arbutus Biopharma Corporation's business model?
Arbutus Biopharma operates in the biopharmaceutical sector, focusing on discovering and commercializing innovative therapies for chronic hepatitis B virus (HBV) infection. The company generates revenue through the development and potential commercialization of antiviral therapies, particularly leveraging its proprietary RNA interference technology to enhance immune response and target the virus.
What is the highest forecasted price for ABUS Arbutus Biopharma Corporation?
The highest price target for ABUS is $7.18 from at , which represents a 122.4% increase from the current price of $3.23.
What is the lowest forecasted price for ABUS Arbutus Biopharma Corporation?
The lowest price target for ABUS is $4.12 from at , which represents a 27.5% increase from the current price of $3.23.
What is the overall ABUS consensus from analysts for Arbutus Biopharma Corporation?
The overall analyst consensus for ABUS is bullish. Out of 9 Wall Street analysts, 3 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $5.14.
How accurate are ABUS stock price projections?
Stock price projections, including those for Arbutus Biopharma Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 3:50 PM UTC